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ABSTRACT
Background: Solifenacin succinate is an antimuscarinic drug with reported 
efficacy and tolerability at a recommended starting dose of 5 mg QD in patients with 
overactive bladder (OAB).
Objective: The objective of this trial was to investigate the efficacy, safety, and 
tolerability of solifenacin 10 mg QD in patients with OAB.
Methods: In this multicenter, Phase III, double-blind, placebo-controlled, 
parallel-group trial, patients aged ≥18 years with OAB were randomized at a 1:1 ratio 
to receive solifenacin 10 mg or placebo QD for 12 weeks. The patients were instructed 
to complete a micturition diary for the 3 days preceding each scheduled visit (weeks 4, 
8, and 12). The primary end point was the change from baseline in the mean number 
of micturitions per 24 hours; secondary end points included the mean change 
from baseline in the number of episodes per 24 hours of urgency, incontinence, noc-
turnal voiding, and nocturia and the mean volume voided per micturition. Tolerability was 
monitored through adverse events (AEs), vital sign measurements, ECGs, laboratory as-
sessments, and physical examination. 
Results: A total of 672 patients were randomized and received ≥1 dose of study 
drug (solifenacin, n = 340; placebo, n = 332). The mean (SE) decrease from baseline 
to study end in the number of micturitions per 24 hours was significantly greater in 
the solifenacin group compared with the placebo group (–3.0 [0.2] vs –1.5 [0.2], re-
spectively; P < 0.001). The mean decrease in the number of episodes of incontinence 
was significantly greater in the solifenacin group compared with the placebo group 
(–2.0 [0.2] vs –1.1 [0.2]; P < 0.001), as was the mean decrease in the number of epi-
sodes of urgency (–4.1 [0.2] vs –2.1 [0.2]; P < 0.001). Of the patients with ≥1 incon-
tinence episode per 24 hours at baseline, significantly more patients in the solifena- 
cin group achieved complete continence at study end than did patients in the placebo 
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group (119/225 [52.9%] vs 80/237 [33.8%]; P < 0.001). The change from baseline 
to study end in the mean volume voided per micturition increased significantly in the 
solifenacin group compared with the placebo group (47.2 vs 2.7 mL; P < 0.001). Most 
AEs were mild or moderate in intensity. The AEs that were most commonly re-
ported in the solifenacin-treated group were anticholinergic in nature: dry mouth 
(91 [26.8%] vs 13 patients [3.9%] in the placebo group; P < 0.001); constipation 
(58 [17.1%] vs 11 [3.3%]; P < 0.001); and blurred vision (12 [3.5%] vs 4 [1.2%]; 
P < 0.05). Serious AEs (SAEs) were reported for 5 patients in the solifenacin 
group and 3 patients in the placebo group. In the solifenacin group, 2 patients expe-
rienced chest pain, 1 had cellulitis, 1 had dehydration, and 1 had colonic obstruction; only 
1 SAE (colonic obstruction) was judged to be possibly related to the study drug. In 
the placebo group, 1 patient had chest pain, 1 had bacterial meningitis, and 1 had 
hemopericardium. 
Conclusions: This study found that solifenacin 10 mg QD for 12 weeks was 
associated with significantly reduced symptoms of OAB, including the frequency of 
micturition, and episodes of urgency and of incontinence. With solifenacin, the vol-
ume voided per micturition increased by 47.2 mL, and 53% of patients with ≥1 in-
continence episode per 24 hours at baseline achieved complete continence. This efficacy 
was accompanied by a favorable safety and tolerability profile. (Curr Ther Res Clin Exp. 
2009;70:405–420) © 2009 Excerpta Medica Inc.
Key words: anticholinergic, incontinence, overactive bladder, solifenacin, 
urgency.
INTRODUCTION
Overactive bladder (OAB) is a symptom syndrome suffered by many individuals1,2 
and is defined by the International Continence Society as “urgency, with or without 
urge incontinence, usually with frequency and nocturia, in the absence of pathologic 
or metabolic conditions that might explain these symptoms.”3 OAB syndrome is a 
highly prevalent condition with serious quality of life (QoL) and socioeconomic 
consequences.4 The US-based National Overactive Bladder Evaluation (NOBLE) 
program has estimated that, overall, 16.2% of men and 16.9% of women have symp-
toms of OAB, representing 33 million sufferers in the United States.5 These figures 
concur with a European population-based survey, which found an OAB prevalence of 
15.6% in men and 17.4% in women. The study also confirmed age as a risk factor, 
with the prevalence of an urgency−frequency syndrome rising to 41.9% of men and 
31.3% of women in those aged ≥75 years.4 
OAB syndrome is associated with a range of complications and comorbidities, in-
cluding urinary tract infection, skin ulceration in patients with wet OAB (defined as 
urgency and frequency with urinary incontinence) and an increased risk of falls in the 
elderly.6,7 Further effects of OAB on QoL include diminished physical, psychosocial, 
occupational, and sexual function,8 which may be seen in OAB patients both with and 
without incontinence.9 This is an important aspect of the syndrome, as the majority 
of patients (66%) have dry OAB (defined as urgency and frequency without urinary 
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incontinence).10 A lack of understanding of the severity of the impact of dry OAB on 
QoL may play a role in the undertreatment of this condition.11 In addition to the 
debilitating effects on the physical, social, and emotional functioning of patients, 
OAB may have a large financial impact. In 2000, the estimated total cost associated 
with OAB in the United States was >$12 billion, an amount comparable to that of 
gynecologic and breast cancers ($11.1 billion) and osteoporosis ($13.8 billion).12
For patients with OAB, antimuscarinic therapy remains the primary pharmaco-
therapeutic option.13,14 However, while antimuscarinic drugs are effective, they are 
often associated with unwanted adverse events (AEs).15,16 Therefore, effective anti-
muscarinic treatments with improved tolerability profiles are required. Solifenacin 
succinate is an antimuscarinic drug that has reported good efficacy and tolerability in 
a Phase III clinical development program.17,18 It is recommended (and approved) at a 
dose of 5 mg QD, which may be increased to 10 mg QD if required and if the 5-mg 
dose is well tolerated.19 The findings of 2 randomized, double-blind, placebo-controlled 
trials indicated that treatment with solifenacin 5 and 10 mg QD was significantly better 
than placebo in improving all symptoms of OAB, including frequency, urgency, incon-
tinence, and volume voided.17,18 In a separate Phase IIIb study,20 solifenacin was found 
to be significantly more effective (P = 0.035) at reducing episodes of urgency than tol- 
terodine extended release (ER). In addition, solifenacin was significantly more effective 
than tolterodine ER on a range of other efficacy variables, including overall incontinence 
(P = 0.006), urge incontinence (P = 0.001), pad use (P = 0.023), and volume voided 
per micturition (P = 0.010). Solifenacin treatment was also found to be noninferior to 
tolterodine for the frequency of micturitions (P = 0.004 for noninferiority).20 All 3 studies 
reported an acceptable tolerability profile for solifenacin.17,18,20
Although the recommended starting dose of solifenacin is 5 mg QD, the ability to 
improve efficacy while maintaining a good tolerability profile at the higher 10-mg dose 
suggests that there is considerable scope for flexible dosing.17,18,20 
The aim of this study was to assess the efficacy, safety, and tolerability of solifenacin 
10 mg* QD in patients with OAB.
PATIENTS AND METHODS
Study Design
This multicenter, Phase III, randomized, double-blind, placebo-controlled, parallel- 
group trial was designed to determine the efficacy, safety, and tolerability of solifenacin 
10 mg in the treatment of OAB. The study consisted of a 2-week screening/washout 
period, a 12-week double-blind treatment period, and a 2-week posttreatment follow-
up assessment for those patients who did not enter an open-label extension study.
Men and women aged ≥18 years with a diagnosis of OAB made by an investigator 
based on symptoms (urinary frequency, urgency, or urge incontinence) were eligible to 
enter the 2-week screening phase. Patients were required to keep micturition diaries 
for 3 days during the screening period. To be eligible for inclusion in the randomiza-
tion phase, patients had to have recorded a mean of ≥8 micturitions per 24 hours 
*Trademark: VESIcare® (Astellas Pharma Inc., Tokyo, Japan).
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plus a mean of ≥1 incontinence episode per 24 hours and/or a mean of ≥1 urgency episode 
per 24 hours during the screening period.
Exclusion criteria included stress urinary incontinence or mixed urinary inconti-
nence in which stress was predominant (mixed incontinence was otherwise allowed), 
a neurologic cause of detrusor overactivity, urinary retention, grade III/IV prolapse 
with cystocele, and recurrent or active urinary tract infection. Patients with abnormal 
findings on 12-lead ECG or abnormal laboratory findings were also excluded. Women 
of childbearing potential were required to have a negative serum pregnancy test at 
screening and to use a medically acceptable form of contraception during study 
participation.
The study was conducted in 33 centers across the United States between February 
2001 and October 2001. Participants were recruited from existing patients in the 
centers’ databases and also through advertisements and a national call center. The 
screening process yielded patients who were eligible for entry into the 12-week, 
double-blind treatment period. Patients were randomized at a ratio of 1:1 to receive 
either solifenacin 10 mg or placebo orally QD, supplied in identical blister packs to 
maintain blinding. The solifenacin and placebo tablets were also identical in appear-
ance. Each pack had a blinded tear-off label containing the name of the product and 
the dose, which was to be used only if it became necessary to unblind the patient. 
Randomization was performed at the center level to provide a balance of treatment 
groups within a center. PROC PLAN (SAS Institute Inc., Cary, North Carolina) 
was used to generate the randomization codes.21 In addition, sealed copies of the 
randomization code were kept by Covance Drug Safety Coordination United States 
(Nashville, Tennessee). 
Both solifenacin and the placebo were manufactured by Yamanouchi Pharmaceutical 
Co., Ltd. (Takahagi, Japan) and were formulated as tablets by Yamanouchi Technologies, 
Inc. (Palo Alto, California).
The patients were instructed to complete a micturition diary for the 3 days preced-
ing each scheduled visit (weeks 4, 8, and 12). The patients recorded the date and time 
of micturitions and episodes of incontinence and urgency. The mean volume voided per 
micturition was recorded on any 2 of the 3 days. The patients also recorded the time 
they went to bed and the time they awoke. When recording micturitions, patients 
also filled out a check box indicating whether or not the micturition awakened them. 
Nocturnal voids were captured as all micturitions that occurred between the time the 
patient reported going to bed and the reported time of awakening. Episodes of noc-
turia were captured as micturitions that woke the patient from sleep between the time 
the patient reported going to bed and the time he or she reported awakening.
The study was performed in accordance with the International Conference on 
Harmonisation Guideline for Good Clinical Practice and the principles of the Declaration 
of Helsinki. The study protocol, informed-consent form, and investigator’s brochure 
were reviewed by a central institutional review board (IRB) (Schulman Associates 
Institutional Review Board, Cincinnati, Ohio) and by the IRB at each study site. All 
patients were informed of the nature and purpose of the study, and written informed 
consent was obtained from all study participants before screening.
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Efficacy Assessments
The primary end point was the change in the mean number of micturitions per 
24 hours from baseline to study end, defined as the last available on-treatment visit 
on or before week 12. Secondary end points included the change from baseline to 
study end in the mean number of episodes of urgency, incontinence, nocturnal voiding, 
and nocturia per 24 hours and the mean volume voided per micturition.
Safety Assessments
Tolerability was assessed throughout the trial by the investigators by monitoring 
AEs. The Medical Dictionary for Regulatory Activities was used to code AEs.22 The 
investigators categorized the AEs by severity according to standard definitions and 
assessed the causal relationship to study medication based on predetermined defini-
tions of unrelated, possibly related, or probably related. Serious AEs were defined as those 
resulting in death, life-threatening AEs, AEs requiring inpatient hospitalization or 
prolongation of existing hospitalization, and AEs resulting in persistent or signifi- 
cant disability/incapacity, a congenital anomaly/birth defect, or a medically signifi- 
cant event or intervention. Vital signs and ECGs were recorded at screening (week –2), 
baseline (week 0), and at weeks 4, 8, and 12. Laboratory assessments (hematology, 
clinical chemistry, and urinalysis) were also carried out at these times. Physical exami-
nations were performed at screening, baseline, week 12, and at posttreatment 
follow-up. Postvoid residual volume was measured by bladder scan at screening and 
at week 12.
Statistical Analysis
Based on the detection of an active−placebo difference of 1 micturition per 24 hours 
between the treatment group and the placebo group, with an SD of 3, a significance 
level of α = 0.05 (2-sided), and a power of 90%, it was estimated that a sample size 
of 250 patients per treatment arm would be required to complete the study. Assuming 
a dropout rate of 20%, ~630 patients needed to be randomized.
The safety population included all patients who were randomized and received ≥1 dose 
of double-blind treatment. This population was used for the summaries of demo-
graphic and baseline characteristics and the safety analyses. The full analysis set (FAS) 
included all patients who were randomized, received ≥1 dose of double-blind 
study medication, and had baseline (from the 3-day diary of the screening/washout 
period) and on-treatment diary data available. The efficacy analyses were performed 
using the FAS.
All end points and analyses were determined a priori. All statistical comparisons 
were made using 2-sided tests at a significance level of α = 0.05. Continuous variables 
were summarized using descriptive statistics, and frequencies and percentages were 
used to report categoric data. The efficacy analysis was performed on the mean change 
from baseline to study end. The last on-treatment assessment method was used as the 
end point assessment in the analysis. Study groups were compared using ANOVA, 
with terms for center and treatment, if normality assumptions warranted. A Shapiro-
Wilks test was performed to test the normality of the residuals; if the normality 
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assumption was not met, a Van Elteren analysis was to be conducted using center as a 
blocking variable.23 As normality was not met, the nonparametric analysis using the 
Van Elteren method was performed for treatment comparisons.
Study group comparisons of the percentage of patients with incontinence at base-
line who became continent (ie, did not report incontinence in the 3-day diary at study 
end) were based on the Mantel-Haenszel test. Additional analyses were performed on 
the percentage of patients meeting a set of criteria with respect to the number of 
micturitions and episodes of incontinence, nocturnal voiding, and nocturia. The inci-
dence estimates were compared between study groups at each visit and at the study 
end, also using the Mantel-Haenszel test.
RESULTS
Patients
Figure 1 shows the disposition of patients throughout the study. A total of 672 pa- 
tients (549 women, 123 men) were randomized to receive solifenacin 10 mg (272 wom- 
en, 68 men; mean [SD] age, 59 [14] years; weight, 82 [21.3] kg; white race, 287 
[84.4%]) or placebo (277 women, 55 men; mean age, 58 [13] years; weight, 81 
[20.5] kg; white race, 272 [81.9%]) (Table I). Each patient received ≥1 dose of study 
drug. The safety population comprised all randomized patients, while 57 patients 
(8.5%) (solifenacin group, 34/340 patients [10.0%]; placebo group, 23/332 patients 
[6.9%]) were excluded from the efficacy analysis due to the lack of baseline or on-
treatment diary data, leaving 306 solifenacin-treated patients and 309 patients in the 
placebo group in the FAS. The 2 groups were comparable with respect to baseline 
demographic and clinical characteristics.
A total of 128 patients (19.0%) discontinued prematurely; discontinuation rates 
were comparable between groups (70/340 [20.6%] in the solifenacin group vs 58/332 
[17.5%] in the placebo group). Discontinuations due to AEs occurred in 37 [10.9%] 
and 18 patients [5.4%] in the solifenacin and placebo groups, respectively.
Efficacy
The mean (SE) decrease from baseline to study end in the number of micturitions 
per 24 hours was significantly greater in the solifenacin group compared with the 
placebo group (–3.0 [0.2] vs –1.5 [0.2]; P < 0.001) (Figure 2). At baseline, the mean 
number of micturitions per 24 hours was 11.7 (0.2) in the solifenacin group and 
11.5 (0.2) in the placebo group. At study end, the mean number of micturitions per 
24 hours was decreased to 8.7 (0.2) in the solifenacin group and 10.0 (0.2) in the 
placebo group. Solifenacin was associated with a significantly greater decrease in the 
frequency of micturitions per 24 hours compared with placebo at all time points from 
week 4 to study end (all, P < 0.001) (Table II). In addition, a significantly greater 
proportion of patients in the solifenacin group compared with the placebo group 
achieved normalization of micturition (mean no. of micturitions per 24 hours <8) at 
study end (136/306 [44%] vs 83/309 [27%], respectively; P < 0.001). 
The mean (SE) decrease from baseline to study end in the number of episodes of 
incontinence per 24 hours was significantly greater in the solifenacin group compared 
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with the placebo group (–2.0 [0.2] vs –1.1 [0.2], respectively; P < 0.001) (Figure 2). 
At baseline, the mean number of episodes of incontinence per 24 hours in the soli- 
fenacin group (n = 225) was 3.1 (0.2) compared with the 3.0 (0.2) episodes in the 
placebo group (n = 237). At study end, the number of episodes was 1.1 (0.2) and 
1.8 (0.2), respectively. As with the primary efficacy end point, solifenacin was as-
sociated with a significantly greater decrease in the number of episodes of inconti-
nence per 24 hours compared with placebo at all time points from week 4 to the study 
end (all, P < 0.001) (Table II). 
Similarly, the mean (SE) decrease from baseline to study end in the number of epi-
sodes of urgency per 24 hours was significantly greater in the solifenacin group com-
Patients screened
(N = 672)
Patients randomized
(N = 672)
Patients receiving study drug
(N = 672)
Solifenacin 10 mg
(n = 340)
Placebo
(n = 332)
Completed
study
(n = 270)
Discontinued
prematurely
(n = 70)
Completed
study
(n = 274)
Discontinued
prematurely
(n = 58)
Adverse event (37)
Patient lost to follow-up (12)
Withdrawal of consent (8)
Insufficient therapeutic response (4)
Protocol violation (3)
Other (6)
Adverse event (18)
Patient lost to follow-up (14)
Withdrawal of consent (15)
Protocol violation (4)
Insufficient therapeutic response (3)
Patient died (1)
Other (6)
Figure 1. Patient disposition throughout the study.
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pared with the placebo group (– 4.1 [0.2] vs –2.5 [0.2]; P < 0.001). The mean number 
of episodes of urgency per 24 hours in the solifenacin group (n = 305) and the placebo 
group (n = 306) was 6.9 (0.2) and 7.2 (0.2), respectively, at baseline. At study end, 
these values were reduced to 2.8 (0.2) and 4.7 (0.2) episodes per 24 hours, respectively. 
Again, solifenacin was associated with a significantly greater decrease in the number 
of episodes of urgency per 24 hours compared with placebo at all time points from 
week 4 to the study end (all, P < 0.001) (Table II). 
Of the patients who reported ≥1 incontinence episode per 24 hours at baseline in 
the solifenacin (n = 225) and the placebo (n = 237) groups, significantly more patients 
in the solifenacin group than the placebo group achieved complete continence at study 
end (119/225 [52.9%] vs 80/237 [33.8%], respectively; P < 0.001). 
The change from baseline to study end in the mean volume voided per micturition 
increased significantly in the solifenacin group (n = 308) compared with the placebo 
group (n = 305) (47.2 vs 2.7 mL, respectively; P < 0.001) (Figure 3).
The number of nocturnal voiding episodes per 24 hours and the number of nocturia 
episodes per 24 hours were both significantly reduced in the solifenacin group com-
pared with the placebo group at week 4 (nocturnal voiding episodes: solifenacin, 
Table I.  Baseline demographic and clinical characteristics of the safety population 
(N = 672).
 Solifenacin  Placebo  
Characteristic (n = 340)  (n = 332)
Age, mean (SD), y 59 (14) 58 (13)
Sex, no. (%)  
  Women 272 (80.0) 277 (83.4)
  Men 68 (20.0) 55 (16.6)
Race, no. (%)  
  White 287 (84.4) 272 (81.9)
  African American 28 (8.2) 42 (12.7)
  Hispanic 17 (5.0) 13 (3.9) 
  Asian 4 (1.2) 3 (0.9)
  Other 4 (1.2) 2 (0.6)
Weight, mean (SD), kg 82 (21.3) 81 (20.5)
Time since start of OAB symptoms, mean (SD), y 9 (10.3) 9 (10.2)
Urge incontinence only, no. (%) 161 (47.4) 163 (49.1)
Mixed stress/urge incontinence with urge as  
predominant factor, no. (%) 178 (52.4) 165 (49.7)
Prior anticholinergic drug therapy, no. (%) 142 (41.8) 111 (33.4)
History of nondrug treatment of OAB, no. (%) 80 (23.5) 80 (24.1)
OAB = overactive bladder.
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–0.5 [n = 282] and placebo –0.4 [291], P < 0.05; nocturia episodes: solifenacin, 
–0.5 [266] and placebo, –0.3 [278], P < 0.05); however, these differences were not 
statistically significant at study end (number of nocturnal voiding episodes: solifenacin, 
–0.7 [n = 283] and placebo, –0.5 [292]; nocturia episodes: solifenacin, –0.6 [267] and 
placebo, –0.4 [279]).
Safety
AEs were reported by 236 (69.4%) and 197 patients (59.3%) in the solifenacin 
and placebo groups, respectively. Most of the patients experienced AEs that were mild 
or moderate in intensity; 44 patients (12.9%) in the solifenacin group and 24 patients 
(7.2%) in the placebo group experienced AEs that were judged to be severe in inten-
sity. The majority of AEs that were most commonly reported in the solifenacin-treated 
group were anticholinergic in nature: dry mouth (91 [26.8%] vs 13 [3.9%] patients 
in the placebo group; P < 0.001); constipation (58 [17.1%] vs 11 [3.3%]; P < 0.001); 
and blurred vision (12 [3.5%] vs 4 [1.2%]; P < 0.05) (Table III).
Frequently reported AEs experienced by the study patients, other than the com-
mon anticholinergic AEs reported previously, are shown in Table IV. The most fre-
quently occurring of these AEs in the solifenacin and placebo group, respectively, were 
found in the following system organ classes: gastrointestinal disorders (154 [45.3%] 
vs 77 [23.2%] patients); infections and infestations (55 [16.2%] vs 52 [15.7%]); and 
nervous system disorders (41 [12.1%] vs 45 [13.6%]). 
Serious AEs (SAEs) were reported for 5 patients in the solifenacin group and 3 pa- 
tients in the placebo group. In the solifenacin group, 2 patients experienced chest 
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Figure 2.  Mean change in the number of overactive bladder symptoms per 24 hours from 
baseline to study end in adult patients with overactive bladder. *P < 0.001 
versus placebo. 
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Table II. Change from baseline in the number of overactive bladder symptoms per 24 hours, by visit. Data are mean (SE).
Week 4 Week 8 Week 12 Study End
Variable Solifenacin Placebo Solifenacin Placebo Solifenacin Placebo Solifenacin Placebo
Micturitions per 
24 hours –2.5 (0.14)* –1.3 (0.14) –2.7 (0.16)* –1.4 (0.14) –2.9 (0.16)* –1.5 (0.16) –3.0 (0.15)* –1.5 (0.15)
Incontinence 
episodes per 
24 hours –1.8 (0.19)* –1.0 (0.14) –2.0 (0.17)* –1.2 (0.16) –2.2 (0.19)* –1.2 (0.18) –2.0 (0.19)* –1.1 (0.16)
Urgency 
episodes per 
24 hours –3.5 (0.20)* –1.9 (0.19) –3.7 (0.21)* –2.4 (0.20) –4.0 (0.21)* –2.4 (0.22) –4.1 (0.20)* –2.5 (0.20)
*P < 0.001 versus placebo.
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pain, 1 had cellulitis, 1 had dehydration, and 1 had colonic obstruction. In the placebo 
group, 1 patient had chest pain, 1 had bacterial meningitis, and 1 had hemopericar-
dium. Only 1 SAE (colonic obstruction) was judged to be possibly related to the study 
drug and occurred in the solifenacin group. 
Thirty-seven patients (10.9%) in the solifenacin group and 23 patients (6.9%) in 
the placebo group discontinued study medication due to an AE. The anticholinergic 
AEs of dry mouth, constipation, blurred vision, and nausea were the most common 
AEs leading to discontinuation. The discontinuation rates in the solifenacin and 
placebo groups due to these AEs were as follows: dry mouth (12 [3.5%] vs 
1 [0.3%], respectively); constipation (12 [3.5%] vs 0 [0%]); blurred vision (5 [1.5%] 
vs 0 [0%]); and nausea (7 [2.1%] vs 3 [0.9%]). No other AE led to discontinuation 
for >1% of the patients in either treatment group.
Solifenacin had no influence on clinical laboratory parameters or vital signs. Mean 
baseline QTc was 422.5 and 421.2 msec in the solifenacin (n = 220) and placebo (n = 
227) groups, respectively; mean (SE) change from baseline was 4.9 (1.29) and 
1.3 (1.24) msec, respectively. The small increase of 3.6 msec in the mean QTc change 
from baseline in the solifenacin group was statistically significant (P = 0.018), but not 
deemed clinically significant.
DISCUSSION
OAB syndrome can have a major impact on patient health-related QoL. Solifenacin is 
a once-daily oral antimuscarinic drug that is indicated for the treatment of OAB at 
doses of 5 and 10 mg; this provides flexibility of dosing, particularly for patients who 
require the greater clinical efficacy of solifenacin 10 mg.
Figure 3.  Mean change from baseline in volume voided (mL)/micturition by visit in adult 
patients with overactive bladder. *P < 0.001 versus placebo.
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Table III.  Common antimuscarinic adverse events (AEs) by treatment group (N = 672). Data are number (%) of patients.
                  Solifenacin 10 mg (n = 340) Placebo (n = 332)
AE Mild Moderate Severe Overall Mild Moderate Severe Overall
Dry mouth 48 (14.1) 35 (10.3) 8 (2.4) 91 (26.8)* 9 (2.7) 4 (1.2)     0 13 (3.9)
Constipation 26 (7.6) 25 (7.4) 7 (2.1) 58 (17.1)* 7 (2.1) 4 (1.2)     0 11 (3.3)
Blurred vision   7 (2.1)   3 (0.9) 2 (0.6) 12 (3.5)† 4 (1.2) 0 (0.0)     0   4 (1.2)
*P < 0.001 versus placebo.
†  P < 0.05 versus placebo.
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In the current study, treatment with solifenacin suggested a significant reduction 
in the primary end point, the number of micturitions per 24 hours, compared with 
placebo (P < 0.001). Analysis of the secondary end point, urgency, showed that the 
number of urgency episodes per 24 hours was reduced by 60% from baseline follow-
ing treatment with solifenacin, whereas the reduction was 35% in the placebo arm 
(P < 0.001). Similarly, the number of incontinence episodes during a 24-hour period 
was significantly reduced in the solifenacin group compared with the placebo group 
(P < 0.001). Of the patients who reported ≥1 incontinence episode at baseline, 53% 
of those treated with solifenacin 10 mg achieved complete continence at study end, 
compared with 34% in the placebo group (P < 0.001). The percentage of patients 
achieving total dryness is not only an important variable in clinical trials of OAB 
treatments, it is one of the most significant factors in the clinician’s choice of thera-
peutic agents and the patient’s perception of benefits. Furthermore, reductions in the 
episodes of micturition, incontinence, and urgency with solifenacin were observed at 
the first assessment at week 4 and were maintained throughout the study period.
Table IV.  Adverse events (AEs), excluding common antimuscarinic events, occurring in 
≥2% of study patients (N = 672). Data are number (%) of patients.
AE
Solifenacin 
(n = 340)
Placebo  
(n = 332)
Gastrointestinal disorders 154 (45.3) 77 (23.2)
  Nausea   19 (5.6) 13 (3.9)
  Dyspepsia   16 (4.7)   3 (0.9)
  Diarrhea     7 (2.1) 15 (4.5)
Infections and infestations   55 (16.2) 52 (15.7)
   Urinary tract infection (not otherwise specified)   21 (6.2) 11 (3.3)
  Nasopharyngitis     3 (0.9) 11 (3.3)
   Upper respiratory tract infection     6 (1.8)   7 (2.1)
Nervous system disorders   41 (12.1) 45 (13.6)
  Headache   16 (4.7) 24 (7.2)
  Dizziness (excluding vertigo)   10 (2.9)     8 (2.4)
Musculoskeletal, connective tissue, and bone disorders   33 (9.7) 37 (11.1)
  Arthralgia     6 (1.8) 11 (3.3)
  Back pain     6 (1.8)   7 (2.1)
Eye disorders (all, including blurred vision)   24 (7.1) 14 (4.2)
Renal and urinary disorders   16 (4.7) 11 (3.3)
Urinary retention     7 (2.1)   3 (0.9)
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The efficacy findings reported here are consistent with those from previous 
studies.17,18,20 Two randomized, double-blind, placebo-controlled, 12-week trials17,18 
found that solifenacin at doses of 5 and 10 mg QD was associated with significantly 
greater decreases in the number of micturitions, urgency episodes, and urge inconti-
nence episodes compared with placebo. In addition, a recent study comparing the 
efficacy of solifenacin (5 or 10 mg QD) with tolterodine ER (4 mg QD) in OAB pa-
tients found that, with a flexible-dosing regimen, solifenacin was associated with 
greater efficacy than tolterodine in decreasing urgency episodes, incontinence, urge 
incontinence, and pad use and increasing the volume voided per micturition; solifena-
cin also demonstrated noninferiority to tolterodine in improving micturition 
frequency.20
Mean voided volume, a secondary end point in the present study, increased significantly 
in the solifenacin group compared with the placebo group. As mean voided volume is the 
most objective parameter in measuring treatment efficacy, the large increase in the present 
study and previous studies supports the efficacy of solifenacin 10 mg QD.
Episodes of nocturia and nocturnal voiding were also decreased significantly in 
patients treated with solifenacin compared with placebo at week 4. However, these 
differences were not statistically significant at study end. In a previous study, episodes 
of nocturia were significantly decreased in patients treated with solifenacin 10 mg versus 
placebo (P = 0.036).17 In general, few studies have assessed the effects of antimuscar-
inic treatment on nocturia, and none have reported any statistically significant effi-
cacy. This is largely due to the multifactorial nature of nocturia. In addition, it is 
difficult to design trials to investigate the effects of antimuscarinic drugs on nocturia 
due to the lower incidence of symptoms and the requirement of large numbers of 
patients to detect statistically significant beneficial effects.24
The results of any clinical trial must always be considered in the context of the 
limitations of that particular study. The limitations of this study may include the use 
of the FAS for the analysis of the efficacy variables. However, this set represents the 
population that is as close as possible to the ideal implied by the intention-to-treat 
principle and conforms to the International Conference on Harmonisation E9 guide-
lines.25 The decision to use the FAS was made a priori. Furthermore, a similar small 
number of patients was excluded from each treatment arm in the FAS (23 patients in 
the placebo group and 34 patients in the solifenacin group). Another potential limita-
tion of this study was the relatively high patient-withdrawal rates (solifenacin group, 
70/340 [20.6%] vs placebo group, 58/332 [17.5%]). These percentages were similar 
in the 2 treatment groups, although an AE as a reason for discontinuation was re-
ported in 37 patients in the solifenacin group and 18 patients in the placebo group; 
the difference was not significant. The discontinuations would not have been expected 
to affect the outcome of the study.
Solifenacin was well tolerated in the current study; the majority of AEs most 
commonly reported for solifenacin were anticholinergic in nature, as anticipated. 
Reasons for study withdrawal were similar in both treatment groups. The anticipated 
anticholinergic AEs of dry mouth, constipation, blurred vision, and nausea were the 
most common AEs leading to discontinuation in the active-treatment arm.
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CONCLUSIONS
This study found that solifenacin 10 mg QD for 12 weeks was associated with signifi-
cantly reducing symptoms of OAB, including the frequency of micturition and of epi-
sodes of urgency and incontinence per 24 hours, compared with placebo. With soli- 
fenacin, the volume voided per micturition increased by 47.2 mL, and 53% of patients 
with ≥1 incontinence episode per 24 hours achieved total continence. This efficacy was 
accompanied by a favorable tolerability profile, as the AEs experienced by the solifenacin 
recipients were mostly mild and anticholinergic in nature. This study supports the ef-
ficacy and safety profile of solifenacin 10 mg in this population of OAB patients.
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